

Accepted Manuscript

Should we Use Cell of Origin and Dual-Protein Expression in Treating DLBCL?

Peter A. Riedell, MD, Sonali Smith, MD

PII: S2152-2650(17)31568-9

DOI: [10.1016/j.clml.2017.12.003](https://doi.org/10.1016/j.clml.2017.12.003)

Reference: CLML 1043

To appear in: *Clinical Lymphoma, Myeloma and Leukemia*

Received Date: 26 September 2017

Revised Date: 8 December 2017

Accepted Date: 18 December 2017

Please cite this article as: Riedell PA, Smith S, Should we Use Cell of Origin and Dual-Protein Expression in Treating DLBCL?, *Clinical Lymphoma, Myeloma and Leukemia* (2018), doi: 10.1016/j.clml.2017.12.003.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



TITLE: Should we use cell of origin and dual-protein expression in treating DLBCL?

RUNNING TITLE: Cell of origin and dual-protein expression in DLBCL

AUTHORS: Peter A. Riedell, MD¹, Sonali Smith, MD¹

AFFILIATION:

¹Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL

CORRESPONDING AUTHOR:

Sonali Smith, MD
Section of Hematology/Oncology
Department of Medicine
The University of Chicago
5841 S. Maryland Ave., MC 2115
Chicago, IL 60637
Phone: 773-702-4400
Fax: 773-702-0963
Email: smsmith@medicine.bsd.uchicago.edu

ACKNOWLEDGMENTS OF RESEARCH SUPPORT: None

KEYWORDS: cell of origin, dual-protein expression lymphoma, double-hit lymphoma, DLBCL, GCB, ABC, non-GCB, NHL

Download English Version:

<https://daneshyari.com/en/article/8615605>

Download Persian Version:

<https://daneshyari.com/article/8615605>

[Daneshyari.com](https://daneshyari.com)